Uloko Mustapha A*

Department of Human Physiology, Ahmadu Bello University Zaria, Nigeria

*Corresponding Author: Uloko Mustapha A, Department of Human Physiology, Ahmadu Bello University Zaria, Nigeria.

Received: October 25, 2023; Published: November 29, 2023

Abstract

Cannabis is the most widely used illicit drug after nicotine and alcohol and can impair several aspect of cognitive functions. It is the flowering or fruiting top of a cannabis plant from which the resin has not yet been extracted. This study was aimed at assessing the effect of Cannabis Sativa on cognitive function. Haloperidol (an antipsychotic drug) blocks the dopaminergic pathways in the brain. Thus, it is expected that administration of haloperidol cause cognitive decline. A total of forty-six (46) adult Wistar rats of both sexes were used for this study. Animals were housed in a conducive environment as expected and were fed regularly with standard animals feed and allowed to acclimatize for two weeks before commencement of the study which lasted for two weeks. Group I served as normal control and were administered 1 ml distilled water. Group II were administered Haloperidol 2 mg/kg, Group III, IV and V were administered cannabis and haloperidol in the following proportions; 5 mg/kg + 2 mg/kg haloperidol, 10 mg/kg + 2 mg/kg haloperidol and 20 mg/kg + 2 mg/kg haloperidol respectively. Group VI, VII and VIII were administered cannabis only in the following proportion; 5 mg/kg, 10 mg/kg and 20 mg/kg respectively. The result of this studies shows that there was no statistically significant difference (P > 0.05) observed in all the treated groups compared to the normal control, there was however an increase in all the groups compared to the control. Based on the result obtained, it may be suggested that cannabis may increase short term memory.

Keywords: Cannabis; Haloperidol; Dopamine; Cognition; Memory

References

1. Ehrenreich H., et al. “Specific Attentional Dysfunction in Adults Following Early Start of Cannabis Use”. Psychopharmacology 142 (1999): 295-301.
2. Ranganathan M and D’Souza DC. “The Acute Effects of Cannabinoids on Memory in mice”. (2006).
3. Castellano C., et al. “Cannabinoids and Memory: Animal Model”. Current Drug Targets CNS Neural Disorder 2 (2003): 389-402.
4. Gloss D. “An Overview of Products and Bias in Research”. Neurotherapeutics 4 (2015): 731-734.
5. Radwan MM., et al. “Isolation and Pharmacological Evaluation of Minor Cannabinoids from High-Potency Cannabis sativa”. Journal of Natural Products 6 (2015): 1271-1276.
6. ElSohly and Gul W. “Handbook of cannabis (Chapter 2). Oxford, UK: Oxford University Press (2014): 20.
7. “American Herbal Pharmacopoeia”. Cannabis inflorescence: Cannabis spp.: Standards of Identity, analysis, and quality control. Scott’s Valley, CA: American Herbal Pharmacopoeia (2013).
8. Grotenhermen F. “Pharmacokinetics and Pharmacodynamics of Cannabinoids”. Clinical Pharmacokinetic 4 (2003): 327-360.
9. Howlett AC. “The Cannabinoid Receptors”. Prostaglandins Other Lipid Mediat 68-69 (2002): 619-631.
10. Ilgen MA., et al. “Characteristics of Adults Seeking Medical Marijuana Certification”. Drug and Alcohol Dependence 3 (2013): 654-659.
11. Bradford AC and WD Bradford. “Medical Marijuana Laws Reduce Prescription Medication Use In Medicare Part D”. Health Affairs 7 (2016): 1230-1236.
12. Prum Jr., et al. “Primary Open-Angle Glaucoma Preferred Practice Pattern^® Guidelines”. Ophthalmology 1 (2016): P41-P111.
13. IOM (Institute of Medicine). “Marijuana and medicine: Assessing the science base”. Washington, DC: National Academy Press (1999).
14. Abel EL. “Cannabis: Effects on Hunger and Thirst”. Behavioral Biology 3 (1975): 255-281.
15. National Institues of Health. “The Dementias”. Hope Through Research (2013).
16. Krishnan S., et al. “Cannabinoids for the treatment of dementia”. Cochrane Database of Systematic Reviews 2 (2009): CD007204.
17. Baker D., et al. “The Therapeutic Potential Cannabis”. The Lancet Neurology 2 (2003): 291-298.
18. Grundy RI. “The Therapeutic Potential of the Cannabinoids in Neuroprotection”. Expert Opinion on Investigational Drugs 11 (2002): 1365-1374.
19. Hampson AJ., et al. “Cannabidiol and Delta-9 Tetrahydrocannabinol are Neuroprotective Antioxidants”. Proceedings of the National Academy of Sciences 95 (1998): 8268-8273.
20. Ehrler MR., et al. “Subjective and Cognitive Effects of Cannabinoids in Marijuana Smokers”. In P. Campolongo and L. Fattore (eds.), Cannabinoid modulation of emotion, memory, and motivation”. New York: Springer (2015): 159-181.
21. Grotenhermen F. “Pharmacokinetics and Pharmacodynamics of Cannabinoids”. Clinical Pharmacokinetic 4 (2003): 327-360.

Citation

Citation: Uloko Mustapha A. “Effect of Cannabis sativa on Cognitive Behavior in Wistar Rats".Acta Scientific Anatomy 2.11 (2023): 10-15.

Copyright

Copyright: © 2023 Uloko Mustapha A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.